Induced pluripotent stem cells in clinical hematology: Potentials, progress, and remaining obstacles

Current Opinion in Hematology

Volumn 19, Issue 4, 2012, Pages 256-260

  Panopoulos, Athanasia D ^a   Belmonte, Juan C I ^a,b  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b CENTER OF REGENERATIVE MEDICINE IN BARCELONA   (Spain)

Author keywords

clinical hematology; hematopoietic differentiation; hematopoietic stem cell; induced pluripotency; reprogramming

Indexed keywords

CELL DIFFERENTIATION; CELL TRANSDIFFERENTIATION; EPIGENETICS; EX VIVO STUDY; GENE TARGETING; GENETIC VARIABILITY; HEMATOLOGIC DISEASE; HEMATOLOGY; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; STEM CELL EXPANSION;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS;

EID: 84862133325     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328353c78f     Document Type: Review

References (34)

1. Doulatov S, Notta F, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell 2012; 10:120-136.
2. Brunstein CG, Wagner JE. Umbilical cord blood transplantation and banking. Annu Rev Med 2006; 57:403-417. (Pubitemid 43261998)
3. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318:1920-1923.
4. Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460:53-59.
5. Wang L, Menendez P, Shojaei F, et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med 2005; 201:1603-1614. (Pubitemid 40721004)
6. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1827.
7. Kyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoidmyeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002; 109:29-37. (Pubitemid 34327514)
8. Notta F, Doulatov S, Laurenti E, et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011; 333:218-221.
9. Szabo E, Rampalli S, Risueno RM, et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010; 468:521-526.
10. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010; 329:1345-1348.
11. Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16:232-236.
12. Csaszar E, Kirouac DC, Yu M, et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell 2012; 10:218-229.
13. Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood 2011; 117:6083-6090.
14. Kimbrel EA, Lu SJ. Potential clinical applications for human pluripotent stem cell-derived blood components. Stem Cells Int 2011; 273076.
15. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481:295-305.
16. Mayshar Y, Ben-David U, Lavon N, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 7:521-531.
17. Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8:106-118.
18. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471:63-67.
19. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471:58-62.
20. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471:68-73.
21. Martins-Taylor K, Nisler BS, Taapken SM, et al. Recurrent copy number variations in human induced pluripotent stem cells. Nat Biotechnol 2011; 29:488-491.
22. Cheng L, Hansen NF, Zhao L, et al. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 2012; 10:337-344.
23. Panopoulos AD, Ruiz S, Izpisua Belmonte JC. iPSCs: induced back to controversy. Cell Stem Cell 2011; 8:347-348.
24. Martins-Taylor K, Xu RH. Concise review: genomic stability of human induced pluripotent stem cells. Stem Cells 2012; 30:22-27.
25. Liu GH, Suzuki K, Qu J, et al. Targeted gene correction of laminopathyassociated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 2011; 8:688-694.
26. Li M, Suzuki K, Qu J, et al. Efficient correction of hemoglobinopathy- causing mutations by homologous recombination in integration-free patient iPSCs. Cell Res 2011; 21:1740-1744.
27. Zou J, Sweeney CL, Chou BK, et al. Oxidase-deficient neutrophils fromX-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011; 117:5561-5672.
28. Zou J, Mali P, Huang X, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011; 118:4599-4608.
29. Soldner F, Laganiere J, Cheng AW, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011; 146:318-331.
30. Howden SE, Gore A, Li Z, et al. Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc Natl Acad Sci USA 2011; 108:6537-6542.
31. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011; 3:97ra80.
32. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011; 3:97ra79.
33. Frantz S. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat Biotechnol 2012; 30:12-13.
34. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012; 379:713-720.